Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06065709
Other study ID # MEDITATION AND PREECLAMPSIA
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 1, 2023
Est. completion date April 1, 2024

Study information

Verified date March 2024
Source University of Gaziantep
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The effect of mindfulness breath awareness meditation on health profile, vital signs, and fetal heart rate in pregnant women with preeclampsia


Description:

The aim of this study is to determine the effect of mindfulness breath awareness meditation (MBAM) on health profile, vital signs, and fetal heart rate in pregnant women with preeclampsia. Sample size: - There will be two groups in the study. - Experiment group is breath awareness meditation group. - The sample size of the study is 66 women. - The sample size will be divided into two and 33 women will be randomly assigned to each group. Application time: - The application will be started after the pregnant women diagnosed with pre-eclampsia is admitted to the Perinatology service. - It will be applied total nine times in once every eight hours during the 72 hours that the pregnant women diagnosed with 20 minutes. - Only mindfulness breath awareness meditation (MBAM) will not be applied to the control group. Care and follow-up will be performed in parallel with the individuals in the experimental group. Data Collection Tools: - Descriptive Information Form - Nottingham Health Profile Scale Measurement time: - Pregnant women will fill in the Introductory Information Form before the first application. - Each session of mindfulness breath awareness meditation practice will 20 minutes. - Pregnant women will fill the Nottingham Health Profile Scale before the first application. It will then be refilled at the same time every 24 hours for 72 hours. The Nottingham Health Profile will be completed a total of four times. - Vital signs (systolic and diastolic blood pressure, body temperature, pulse, respiration, oxygen saturation) will be measured immediately before the first application. They will then be refilled at the same time every 24 hours for 72 hours. Vital signs will be completed a total of four times. - Fetal heart rate and fetal movement count will be measured immediately before the first application. They will then be refilled at the same time every 24 hours for 72 hours. Fetal heart rate and fetal movement count will be assessed by Non-stress Testing (NST). The pregnant woman will undergo NST for 20 minutes.


Recruitment information / eligibility

Status Recruiting
Enrollment 66
Est. completion date April 1, 2024
Est. primary completion date April 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 19 Years to 49 Years
Eligibility Inclusion Criteria: - pregnant women who is admitted to the Perinatology Service of the hospital with the diagnosis of preeclampsia, - who is 19 to 49 years old, - who is 20 and over weeks of gestation, - who followes by at least three days of hospitalization in the ward. Exclusion Criteria: - Pregnant women who do not meet the inclusion criteria and who voluntarily withdraw at any stage after inclusion will be excluded from the study.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Mindfulness breath awareness meditation
Mindfulness breath awareness meditation

Locations

Country Name City State
Turkey Sanliurfa training and research hospital Sanliurfa Eyalet/Yerleske

Sponsors (1)

Lead Sponsor Collaborator
Aysegul Kilicli

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Nottingham Health Profile Nottingham Health Profile The scale consists of 38 questions and 6 sub-dimensions. The scale consists of 8 questions on physical activity (PA), 8 questions on pain (P), 5 questions on sleep (S), 3 questions on energy level (EL), 9 questions on emotional reactions (ER), 5 questions on social isolation (SI). Questions are answered as 'yes' or 'no', item score calculations in each sub-dimension differ, the best score that can be obtained from each sub-dimension is '0' and the worst score is '100'. The minimum score that can be obtained from the whole scale is 0 and the maximum score is 600. Quality of life improves as the score decreases. It will be evaluated before the first application and then every 24 hours for a total of 4 times
Primary Fetal heart rate Fetal heart rate It will be evaluated before the first application and then every 24 hours for a total of 4 times
Primary Body temperature Body temperature It will be evaluated before the first application and then every 24 hours for a total of 4 times
Primary Pulse Pulse It will be evaluated before the first application and then every 24 hours for a total of 4 times
Primary Systolic blood pressure Systolic blood pressure It will be evaluated before the first application and then every 24 hours for a total of 4 times
Primary Diastolic blood pressure Diastolic blood pressure It will be evaluated before the first application and then every 24 hours for a total of 4 times
Primary Respiratory rate Respiratory rate It will be evaluated before the first application and then every 24 hours for a total of 4 times
Primary Oxygen saturation Oxygen saturation It will be evaluated before the first application and then every 24 hours for a total of 4 times
Secondary fetal movement count fetal movement count It will be evaluated before the first application and then every 24 hours for a total of 4 times
Secondary Nottingham Health Profile subdimensions Nottingham Health Profile subdimensions physical activity, pain, sleep, energy, emotional reactions, and social isolation It will be evaluated before the first application and then every 24 hours for a total of 4 times
See also
  Status Clinical Trial Phase
Completed NCT03510286 - Validation of a PrCr Dipstick Diagnostic Test in Ghana
Recruiting NCT03313024 - Berlin-Brandenburg Pregnancy Cohort
Active, not recruiting NCT04990141 - Molecular Screening Method for Preeclampsia (PREMOM)
Completed NCT02147626 - Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia N/A
Not yet recruiting NCT05999851 - Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy N/A
Recruiting NCT02923206 - Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis N/A
Terminated NCT02558023 - The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine Phase 3
Completed NCT02554604 - Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies
Completed NCT02854501 - Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders
Withdrawn NCT05016440 - Lisinopril for Renal Protection in Postpartum Preeclamptic Women N/A
Not yet recruiting NCT02541110 - Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler N/A
Completed NCT02384226 - User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
Recruiting NCT02247297 - Pancreatic Stone Protein (PSP) in Pregnant Women
Recruiting NCT02337049 - Preeclampsia Subtypes and Surrogate Markers of CVD Risk N/A
Completed NCT02238704 - Cornell University-Micronutrient Initiative Calcium Supplementation Study N/A
Completed NCT01195441 - Prediction and Prevention of Preeclampsia by First Trimester Ultrasound N/A
Withdrawn NCT01179542 - The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR N/A
Completed NCT00456118 - Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies
Recruiting NCT00117546 - Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia Phase 4
Completed NCT00787241 - Platelet Count Trends in Pre-eclamptic Parturients N/A